/Johnson%20%26%20Johnson%20baby%20powder-by%20rafapress%20via%20Shutterstock.jpg)
New Brunswick, New Jersey-based Johnson & Johnson (JNJ) is a healthcare company recognized for its leadership in pharmaceuticals, medical technologies, and consumer health products. Valued at a market cap of $428 billion, the company focuses on improving human health and well-being through scientific innovation, patient-centered care, and a commitment to addressing some of the world’s most pressing health challenges. The company is expected to announce its fiscal Q3 earnings for 2025 before the market opens on Tuesday, Oct. 14.
Before this event, analysts project this healthcare giant to report a profit of $2.78 per share, up 14.9% from $2.42 per share in the year-ago quarter. The company has a promising trajectory of consistently beating Wall Street’s bottom-line estimates in each of the last four quarters. Its earnings of $2.77 per share in the previous quarter topped the consensus estimates by 4.1%.
For fiscal 2025, analysts expect JNJ to report a profit of $10.86 per share, up 8.8% from $9.98 per share in fiscal 2024. Its EPS is expected to further grow 4.7% year-over-year to $11.37 in fiscal 2026.
JNJ has lagged behind the S&P 500 Index's ($SPX) 15.4% uptick over the past 52 weeks, with its shares up 10.7% over the same time period. Nonetheless, it has considerably outpaced the Health Care Select Sector SPDR Fund’s (XLV) 12.1% drop over the same time frame.
Shares of Johnson & Johnson soared 6.2% on Jul. 16, after it delivered a better-than-expected Q2 performance. The company’s overall revenue grew 5.8% year-over-year to $23.7 billion, topping consensus estimates by 3.8%. Moreover, while its adjusted EPS of $2.77 declined 1.8% from the year-ago quarter, it also exceeded the analyst estimates by 4.1%.
Wall Street analysts are moderately optimistic about JNJ’s stock, with a "Moderate Buy" rating overall. Among 25 analysts covering the stock, 11 recommend "Strong Buy," two indicate "Moderate Buy," and 12 suggest "Hold.” The mean price target for JNJ is $180.54, indicating a 1.6% potential upside from the current levels.
